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Abstract
Mycobacterium tuberculosis (MTB) remains a major challenge to
global health made worse by the spread of multidrug resistance.
We therefore examined whether stimulating intracellular killing
of mycobacteria through pharmacological enhancement of
macroautophagy might provide a novel therapeutic strategy.
Despite the resistance of MTB to killing by basal autophagy,
cell-based screening of FDA-approved drugs revealed two anti-
convulsants, carbamazepine and valproic acid, that were able to
stimulate autophagic killing of intracellular M. tuberculosis within
primary human macrophages at concentrations achievable in
humans. Using a zebrafish model, we show that carbamazepine
can stimulate autophagy in vivo and enhance clearance of
M. marinum, while in mice infected with a highly virulent multi-
drug-resistant MTB strain, carbamazepine treatment reduced
bacterial burden, improved lung pathology and stimulated
adaptive immunity. We show that carbamazepine induces antimi-
crobial autophagy through a novel, evolutionarily conserved,
mTOR-independent pathway controlled by cellular depletion of
myo-inositol. While strain-specific differences in susceptibility to
in vivo carbamazepine treatment may exist, autophagy enhance-
ment by repurposed drugs provides an easily implementable
potential therapy for the treatment of multidrug-resistant myco-
bacterial infection.
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Introduction
The increase in infections with multidrug-resistant (MDR) and
extensive drug-resistant (XDR) Mycobacterium tuberculosis (MTB),
requiring longer and more toxic drug regimens which often fail, has
created significant barriers to effective treatment of tuberculosis in
both well-resourced and resource-poor settings (Nathanson et al,
2010; Lienhardt et al, 2012) and illustrates the pressing need
for new, more effective therapies. Although some progress has
been made in developing novel antibiotics (www.newtbdrugs.org/
1 Department of Medicine, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
2 Cambridge Centre for Lung Infection, Papworth Hospital, Cambridge, UK
3 Department of Paediatric Infectious Diseases and Allergy, Imperial College London, London, UK
4 Department of Medical Genetics, Cambridge Institute for Medical Research, University of Cambridge, Cambridge, UK
5 Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado, USA
6 Department of Infection and Immunity, University of Sheffield, Western Bank, Sheffield, UK
7 MRC Laboratory of Molecular Biology, Cambridge, UK
8 The Inositide Laboratory, Babraham Institute, Babraham Research Campus, Cambridge, UK
*Corresponding author. Tel: +44 1223 768801; Fax: +44 1223 762640; E-mail: arf27@cam.ac.uk
**Corresponding author. Tel: +44 1223 762608; Fax: +44 1223 762640; E-mail: dcr1000@cam.ac.uk
***Corresponding author. Tel: + 1 970 491 7840; Fax: +1 970 491 1815; E-mail: D.Ordway@colostate.edu
†Contributed equally to this work
‡Deceased
ª 2014 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine Vol 7 | No 2 | 2015 127
pipeline.php), we have pursued an alternative therapeutic strategy
of trying to stimulate intracellular killing of MTB within macro-
phages through pharmacological induction of autophagy.
Autophagy is a fundamental, evolutionarily conserved mecha-
nism used by cells to degrade cytoplasmic protein aggregates and
organelles (Mizushima et al, 2008) but can also target intracellular
bacteria, including M. tuberculosis, for lysosomal degradation
(Gutierrez et al, 2004; Deretic & Levine, 2009). Greater understand-
ing of how M. tuberculosis triggers basal autophagy has recently
emerged, suggesting that ESAT6-dependent phagosome rupture
permits ubiquitin tagging of mycobacteria, LC3 recruitment through
NDP52 and p62 adaptor binding and engagement of TBK1 (Watson
et al, 2012), an enzyme critical for inflammasome activation (Pilli
et al, 2012). However, the mechanisms permitting intracellular
mycobacteria to resist basal autophagic killing and persist within
macrophages remain poorly understood.
Intracellular killing of M. tuberculosis can be enhanced through
mTOR-dependent stimulations of autophagy (Gutierrez et al, 2004).
While effective in vitro, this approach is probably unsuitable for
clinical use, since mTOR inhibition also leads to immunosuppression
(McMahon et al, 2011). We therefore wondered whether there might
be existing clinical drugs that could stimulate mTOR-independent
autophagic killing of M. tuberculosis, which could be rapidly repur-
posed as novel treatments for multidrug-resistant mycobacteria.
Here, we show that screening of FDA-approved drugs identified
compounds able to stimulate autophagic killing of mycobacteria at
therapeutic concentrations. One such compound, carbamazepine,
triggers autophagy independently of mTOR (revealing a novel
myo-inositol-dependent activation pathway) and effectively targets
multidrug-resistant M. tuberculosis in vivo stimulating both innate
and adaptive immunity.
Results
FDA-approved drugs able to stimulate autophagic
killing of mycobacteria
We have previously shown that novel mTOR-independent path-
ways exist to activate autophagy (Sarkar et al, 2005; Williams
et al, 2008). Through high-throughput screening of a library of
214 compounds enriched for drugs already FDA-approved for
non-infectious indications (see Methods), we identified several
compounds able to activate mTOR-independent autophagic killing
of intracellular mycobacteria (after 24-h treatment). We focused
on two anticonvulsant drugs, carbamazepine (CBZ) and valproic
acid (VPA) which stimulated killing of mycobacteria (M. bovis
BCG) within primary human monocyte-derived and alveolar
macrophages at concentrations achievable during therapeutic
dosing, while not affecting mycobacterial survival in the absence
of cells or macrophage viability (Fig 1A–C; Supplementary Fig S1
& Supplementary Table 1). We also found that both CBZ and
VPA stimulated intracellular killing of M. tuberculosis (H37Rv)
within primary human macrophages (Fig 1D). Since the lowest
effective concentration of VPA was at the upper limit of what
might be safely achieved in humans, we focused on CBZ for
further therapeutic evaluation in vivo. In zebrafish expressing
fluorescent ATG8, treatment with CBZ for 24 h (in the presence of
low-dose chloroquine to delay degradation of autophagosomes)
led to a significantly greater accumulation of autophagosomes
than in fish treated with vehicle alone or rapamycin (Fig 1E).
Furthermore, CBZ was also able to enhance clearance of
M. marinum from infected zebrafish embryos (Fig 1F), an estab-
lished model of mycobacterial infection (Lesley & Ramakrishnan,
▸Figure 1. Anticonvulsants stimulate killing of mycobacteria in vitro.A Screening drugs for effects on survival of intracellular mycobacteria in macrophages. RAW 264.7 cells were infected with a luminescent strain of M. bovis BCG (BCG-
lux) for 1 h, washed and treated for 24 h with vehicle alone (white), known autophagy enhancers (interferon-c (IFNc), 200 ng/ml and rapamycin, 200 nM; black),
known mTOR-independent autophagy inhibitor (forskolin; 24 lM; blue), carbamazepine (CBZ, 50 lM; red), valproic acid (VPA, 3 mM; green) and other examples of
hits from a large screen of compounds enhancing intracellular killing of mycobacteria (lithium, 10 mM; rilmenidine, 1 lM; clonidine, 1 lM; calpeptin, 50 lM; grey).
P-values, unpaired Student’s t-test (n ≥ 6) (compared to vehicle alone): IFNc 0.03; rapamycin 0.003, CBZ 0.001, VPA 0.001, lithium 0.001, rilmenidine 0.001;
clonidine 0.02; calpeptin 0.01. Inset: Correlation between measurements of colony-forming units (CFU) and luminescence (RLU) for cultures of M. bovis BCG-lux as
previously described (Kampmann et al, 2000).
B Effects on intracellular survival of M. bovis BCG-lux of treatment with varying concentrations of CBZ (red) or VPA (green). P-values, unpaired Student’s t-test (n = 6)
(compared to vehicle alone) for CBZ 30 lM: 9 × 107, 40 lM: 1.9 × 109, 50 lM: 1.3 × 109, 100 lM: 1.6 × 108, 200 lM: 2.7 × 109, VPA 0.5 mM: 6.9 × 108,
1 mM: 1.6 × 109, 3 mM: 4.3 × 1010, 4 mM: 4.2 × 109, 10 mM: 1.1 × 109, 20 mM: 4.2 × 1010. These compounds had no effect on cell-free mycobacterial
viability (grey circles).
C Anticonvulsants enhance intracellular killing of mycobacteria within human alveolar macrophages. Alveolar macrophages, obtained from the broncho-alveolar
lavage fluid of three individuals, were infected with M. bovis BCG-lux and then treated with carbamazepine (CBZ, 50 lM; red), valproic acid (VPA, 3 mM; green) or
vehicle alone (Con; black). Viable intracellular mycobacteria were determined after 24 h of treatment. Unpaired Student’s t-test (n = 3) (compared to vehicle alone):
CBZ 0.011; VPA 0.0009.
D Enhanced killing of intracellular M. tuberculosis (H37Rv) within primary human macrophages by treatment with CBZ (50 lM; red), VPA (3 mM; green) and
rapamycin (200 nM; black), compared to control (vehicle alone; white). Unpaired Student’s t-test (n = 6) (compared to vehicle alone): rapamycin 48 h 0.00002,
rapamycin 72 h 0.00005, CBZ 48 h 0.00021, CBZ 72 h 0.00022, VPA 48 h 0.0002, VPA 72 h 0.00049.
E In vivo induction of autophagy by CBZ (50 lM; red) and rapamycin (RAP; 1 lM; blue) compared to vehicle control (white) monitored in zebrafish expressing
fluorescent ATG8 co-treated with chloroquine to delay degradation of autophagosomes.
F Wild-type zebrafish were injected with a red fluorescently tagged M. marinum strain M into the yolk sac circulation valley at 28 hpf. Larvae were imaged at 120 hpf
by confocal microscopy and the total mycobacteria-associated fluorescence quantified using Volocity® software. Data expressed as mean  SEM (n ≥ 13 fish
performed as 3 independent experiments). P-values, unpaired Student’s t-test (compared to vehicle alone): 0.0035.
G–I Mice infected via aerosol with a highly virulent clinical strain of multidrug-resistant M. tuberculosis CSU 87 were treated from day 20 post-infection with
carbamazepine (CBZ, 50 lg/kg i.p. daily), rifampicin/isoniazid (RIF/INH) or vehicle control (n = 5 per time point per group). CBZ treatment for 30 days resulted in (G)
significantly less viable bacteria detected in lung and spleen, (H) reduced inflammatory pulmonary infiltrates compared to RIF/INH-treated or control animals and
(I) decreased lung lesion scores. Unpaired Student’s t-test (n = 5) (compared to vehicle alone): RIF/INH 0.007; CBZ 0.037.
Data information: *P < 0.05; **P < 0.005.
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2008). We then determined the impact of CBZ in vivo in a
mouse model of M. tuberculosis infection. Since conventional
antibiotic resistance should not influence autophagic killing of
mycobacteria, we examined the effect of CBZ in mice infected via
aerosol with a highly virulent multidrug-resistant M. tuberculosis
(MDR-TB) strain (CSU 87; Park et al, 2006). Treatment with CBZ
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(at a dose mirroring therapeutic administration in humans)
significantly reduced MDR-TB burden in lungs and spleen, dimin-
ished inflammatory pulmonary infiltrates and decreased lung
lesion scores, whereas treatment with first line anti-mycobacterial
antibiotics rifampicin and isoniazid (RIF/INH), as expected, had
no effect (Fig 1G–I). However, in further studies on mice infected
with a less virulent MDR-TB strain (CSU39; Rhoades & Orme,
1997), or a drug-sensitive isolate (SA310; Palanisamy et al,
2009), CBZ treatment had little or no effect in vivo (Supplemen-
tary Fig S2).
Carbamazepine promotes innate and adaptive immunity during
mycobacterial infection
We found that macrophages infected with mycobacteria demon-
strated autophagy-dependent pro-inflammatory cytokine production
(Fig 2A) and in vitro treatment with CBZ, as well as rapamycin,
increased TNFa and IL-8 release (Fig 2B), potentially through
enhanced degradative generation of ligands for intracellular pattern
recognition receptors. We also examined the effect of CBZ on
cytokine production and other components of host immunity to
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Figure 2. Carbamazepine promotes innate and adaptive immunity during mycobacterial infection.
Primary human macrophages infected with M. bovis BCG were treated with carbamazepine (CBZ, 50 lM) or rapamycin (Rap; 200 nM). IL-8 (black) and TNFa (grey)
were measured in supernatants collected 24 h after infection.
A Levels of IL-8 (black) and TNFa (grey) released by M. bovis BCG-infected primary human macrophages were autophagy dependent, measured following siRNA knock-
down of the critical autophagy protein, ATG12, or control siRNA (control). P-values, unpaired Student’s t-test (n = 3) ATG12 siRNA vs siControl: TNFa 0.0006; IL-8
0.0012.
B Carbamazepine increases pro-inflammatory cytokine secretion by mycobacteria-infected human macrophages. P-values, unpaired Student’s t-test (n = 5) (compared
to vehicle alone): CBZ TNFa 0.00048, IL-8 0.0017; Rap TNFa 0.001, IL-8 0.0089.
C Analysis (by flow cytometry) of intracellular cytokines (IL-27, IL-12, TNFa) and MHC class II surface expression for dendritic cells (CD11c+) and macrophages (CD11b+)
from lung, spleen and draining lymph nodes of mice that were uninfected and untreated (grey), uninfected and CBZ-treated (orange), infected with multidrug-
resistant M. tuberculosis (MDR-TB) and untreated (black), MDR-TB infected and treated with rifampicin and isoniazid (RIF/INH; blue) or MDR-TB infected and treated
with carbamazepine (CBZ, red).
Data Information: *P < 0.05; **P < 0.005. All experiments were carried out at least in triplicate and on at least 2 separate occasions.
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mycobacteria in vivo. Treatment of infected mice with CBZ resulted
in significantly greater TNFa, IL-12 and IL-27 production and MHC
class II surface expression by dendritic cells and macrophages
(Fig 2C), which are all associated with favourable outcomes clini-
cally and suggest that CBZ, in addition to enhancing intracellular
killing, might also promote adaptive immune responses. Supporting
evidence comes from analysis of lung CD4+ T cells tracking
cytokine production as well the kinetics of effector
(CD4+CD44hiCD62lo), and memory (CD4+CD44hiCD62Lhi) T cells
influx. CBZ treatment increases the numbers of central memory and
IFNc-secreting T cells while reducing FoxP3+ IL-10+ regulatory T
cells (Supplementary Fig S3). These findings are in keeping with
previous reports suggesting that autophagy stimulation may
improve antigenic peptide production during mycobacterial infection
(Jagannath et al, 2009). We also noticed a mild pro-inflammatory
effect of CBZ treatment in uninfected animals (Fig. 2C), potentially
reflecting non-specific immune stimulation.
Carbamazepine triggers mTOR-independent autophagy through
depletion of cellular myo-inositol
We then examined the molecular mechanisms of action of CBZ and
VPA. Both compounds enhanced autophagosome synthesis and
clearance of known autophagic substrates in cell lines (Fig 3A and B)
and increased autophagosome numbers in human macrophages,
assessed by LC3 Western blot and confocal microscopy (Fig 3C
and D). We confirmed that CBZ and VPA trigger autophagosome
formation independently of mTOR (Fig 3E). When autophagy was
blocked by siRNA knock-down of ATG12, CBZ and VPA failed to
stimulate clearance of intracellular mycobacteria (M. bovis BCG),
validating that their effects were mediated through enhanced
autophagic killing (Fig 3Fi, ii).
We next focused on the mechanism by which CBZ induced auto-
phagy in human macrophages. We first looked for the presence of
known molecular targets of CBZ in primary human macrophages
and identified the voltage- and stretch-activated sodium (Na+) chan-
nel SCN5A (Supplementary Fig S4; Carrithers et al, 2011), but not
other SCN channels. We observed that SCN5A-blocking dibenzaze-
pines (Lipkind & Fozzard, 2010), but not the cardiac-specific inhibi-
tor flecainide, also enhanced killing of intracellular M. bovis BCG
(Fig 4A), with no adverse cytotoxic effects (Supplementary Fig S5),
suggesting that SCN5A might be the molecular target of CBZ on
macrophages. Since SCN5A may regulate the sodium–inositol co-
transporter, SLC5A3, in neuronal cell lines (as suggested previously;
Yamashita et al, 1999), we tested whether CBZ could induce auto-
phagic clearance of mycobacteria through inhibition of myo-inositol
uptake. Consistent with this model, CBZ blocked Na+-dependent
myo-inositol uptake in macrophages (Fig 4B); siRNA knock-down
of SLC5A3 led to reduced Na+-dependent myo-inositol uptake,
increased autophagosome formation (Supplementary Fig S6) and
enhanced intracellular killing of M. bovis BCG with no additional
effect of CBZ treatment (Fig 4C and D). Furthermore, co-incubation
of macrophages with high concentrations of myo-inositol blocked
the activity of CBZ to enhance intracellular killing of mycobacteria
(Fig 4D) and induce autophagy (Supplementary Fig S7). To confirm
that myo-inositol depletion was sufficient to activate autophagy,
we incubated cells in cell culture media with varying amounts
of myo-inositol and observed stimulation of autophagosome
formation, by both confocal microscopy and Western blot, and
enhanced clearance of autophagic protein substrates (Fig 4E,
Supplementary Fig S7).
Carbamazepine stimulates autophagy through IP3 depletion and
AMPK activation
To further define which signalling components might mediate inosi-
tol-regulated intracellular killing of mycobacteria, we turned to
Dictyostelium, which provides a robust model for examining both
intracellular killing of mycobacteria (Hagedorn et al, 2009) and
inositol signalling (Williams et al, 1999). We first confirmed that
killing of M. abscessus by Dictyostelium was impaired by autophagy
inhibitors (Supplementary Fig S8). Using published deletion
mutants (Traynor et al, 2000; Luo et al, 2003; Kortholt et al, 2007;
Cho et al, 2008), we observed enhanced killing of M. abscessus by
strains deficient in phospholipase c (PLC) or inositol (1,4,5)-tris-
phosphate receptor (IP3R; Fig 5A), suggesting a critical role for IP3
in regulation of autophagic killing. As anticipated following CBZ-
induced depletion of cellular myo-inositol, we also observed reduc-
tions in basal levels of phosphatidylinositol bisphosphate (PIP2;
Fig 5B) and inositol (1,4,5)-trisphosphate (IP3; Fig 5C) in macro-
phages. In agreement with the recently proposed role of basal IP3 in
regulating mitochondrial function and thereby autophagy (Ca´rdenas
et al, 2010), CBZ treatment in macrophages reduced levels of mito-
chondrial calcium (Fig 5D), decreased cellular ATP concentrations
(Fig. 5E) and consequently increased phosphorylation of AMP
kinase and ULK1 (Fig 5F, Supplementary Fig S9), which are estab-
lished triggers of mTOR-independent autophagy (Ca´rdenas et al,
2010; Alers et al, 2011; Egan et al, 2011). These data are consistent
with a model for inositol regulation of autophagic killing in macro-
phages which could potentially be amenable to therapeutic interven-
tion at multiple steps. Thus, depletion of cytosolic myo-inositol
leads to reduced basal IP3 (through decreased available PIP2) which,
by reducing mitochondrial Ca2+ entry, results in decreased ATP
production ultimately activating AMP kinase/ULK1-dependent stim-
ulation of autophagy (Fig 5G).
Discussion
Through mammalian cell-based screening, we have identified FDA-
approved drugs that enhance autophagic killing of mycobacteria
and could rapidly be reprofiled for clinical use. Our lead compound,
the anticonvulsant carbamazepine, is effective against MDR-TB
infection in vivo and thus provides first proof-of-principal that phar-
macological induction of mTOR-independent autophagy can be used
to treat multidrug-resistant mycobacteria. Our finding that carba-
mazepine enhances autophagy through cellular myo-inositol deple-
tion, while suggesting new mechanisms by which it may act in
psychiatric disorders (through altered inositol phosphate signalling
(Berridge et al, 1989; Harwood, 2005) and/or autophagic regulation
of presynaptic neurotransmission (Hernandez et al, 2012)), reveals
a fundamental role for inositol metabolism in triggering autophagy
and has identified a novel, potentially druggable, pathway regulat-
ing autophagy induction in macrophages.
Although carbamazepine was capable of enhancing autophagic
killing by macrophages infected with all strains of drug-sensitive
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Figure 3. Anticonvulsants stimulate autophagosome formation in vitro.
A The anticonvulsants carbamazepine and valproic acid enhance autophagic clearance of cytosolic substrate.Wemonitored the clearance of the known autophagy substrate
(A53T) a-synuclein in stable inducible PC12 cells by Western blot. The A53T a-synuclein transgene was induced with doxycycline for 48 h and then switched off (by
antibiotic removal) before cells were treated with carbamazepine (CBZ, 50 lM; red), valproic acid (VPA, 3 mM; green), rapamycin (Rap, 200 nM; black), forskolin (FSK, 10 lM;
blue) or vehicle alone (DMSO;white) for a further 24 h. P-values, paired Student’s t-test (n = 3) (compared to vehicle alone): Rap 0.0011; CBZ 0.0017; VPA 0.02; FSK 0.005.
B Anticonvulsants enhance autophagosome synthesis in primary human macrophages. In the presence of a saturating concentration of bafilomycin A1 (400 nM) which
blocks autophagosome–lysosome fusion, levels of LC3-II reflect autophagosome production and were quantified in human macrophages (from a different healthy
individual in 3 separate experiments) treated with rapamycin (Rap, 200 nM; black), carbamazepine (CBZ, 50 lM; red), valproic acid (VPA, 3 mM; green) or vehicle
alone (DMSO; white). P-values, paired Student’s t-test (n = 3) (compared to vehicle alone): CBZ 0.026.
C Increases in LC3-II levels (assessed by Western blot) in primary human macrophages infected with M. bovis BCG after 4 h treatment with rapamycin (Rap; 200 nM),
valproic acid (VPA, 3 mM) and carbamazepine (CBZ, 50 lM) compared to controls. P-values, paired Student’s t-test (n = 3) (compared to vehicle alone): Rap 0.02; VPA
0.004; CBZ 0.003.
D Treatment of M. bovis BCG-infected human macrophages with CBZ (50 lM) or VPA (3 mM) increased autophagosome number, assessed by confocal microscopy of
cells stained with LC3-specific antibody (green) with quantification of the number of autophagosomes (defined as LC3 + vesicles ≥ 1 lm diameter) per cell shown
below. P-values, unpaired Student’s t-test (n = 3) (compared to vehicle alone): CBZ 0.001, VPA 0.003. Scale bar represents 10 lm.
E In contrast to rapamycin (Rap), carbamazepine (CBZ) treatment of macrophages, while increasing LC3-II levels, does not alter mTOR-dependent signalling (monitored
by changes in phosphorylation of S6 and p70S6 kinase).
F Enhanced intracellular killing of mycobacteria by anticonvulsants is mediated through autophagy. SiRNA knock-down of ATG12 in primary human macrophages
blocks autophagy leading to (i) reduced LC3-II levels and (ii) loss of CBZ- (50 lM) and VPA- (3 mM) induced enhancement of intracellular killing of M. bovis BCG.
P-values, unpaired Student’s t-test (n = 3) (compared to vehicle alone): Rap 0.002; VPA 0.001; CBZ 0.0001.
Data information: *P < 0.05; **P < 0.005. All experiments were carried out at least in triplicate and on at least 3 separate occasions.
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and drug-resistant mycobacteria tested, we did observe differential,
strain-specific effects when treating M. tuberculosis-infected mice.
Further work will be required to establish whether these treatment
failures reflect inadequate dosing of carbamazepine (which is both
poorly solubilized and susceptible to variable hepatic metabolism)
or true strain-specific differences in susceptibility to CBZ-enhanced
or autophagy-dependent clearance in vivo. Nevertheless, our work
provides firm evidence for the potential of therapeutic autophagy
enhancement and a starting point for the development of more
effective compounds.
In summary, stimulation of autophagy by carbamazepine avoids
the immunosuppressive effects of mTOR inhibition seen with rapa-
mycin, promoting both innate and adaptive immune responses to
mycobacterial infection, and represents a novel therapeutic strategy
unaffected by bacterial resistance to conventional antibiotics. Our
work suggests that while M. tuberculosis can successfully overcome
physiological processes mediating intracellular killing and survive
within macrophages, it remains vulnerable to mTOR-independent
autophagic clearance.
Materials and Methods
In vitro mycobacterial infection assays
Luminescent reporter strain infection
A validated luminescent reporter strain of M. bovis BCG (BCG-lux)
encoding the Vibrio lux AB gene, generated as previously described
(Kampmann et al, 2000), was used to infect macrophages. Correla-
tion between colony-forming units and luminescence was confirmed
prior to experiments. Primary human macrophages (obtained from
consented healthy volunteers under Regional NHS Research Ethics
Committee approval), or the mouse macrophage cell line RAW
264.7 (purchased from ATCC and regularly tested for mycoplasma),
were inoculated with BCG-lux (at MOI of 10:1) for 1 h at 37°C,
repeatedly washed and then incubated for 24 h at 37°C in the pres-
ence of compounds as indicated. Cells were lysed and luminescence
was measured as previously described (Renna et al, 2011). Experi-
ments were carried out in sextuplicate. Results are representative of
three separate experiments.
Screening compounds for autophagic killing activity
Two hundred and fourteen compounds with no direct antibiotic
activity, which have been used in human without major toxicity,
were screened on multiple occasions for their ability to kill intracel-
lular BCG-lux within macrophages (initially the mouse macrophage
cell line RAW 264.7). Hits were then tested both on autophagy-null
(ATG12 KD) cells (to demonstrate autophagy-dependent killing) and
on primary human macrophages, and for their ability to stimulate
mTOR-independent autophagy.
Infection with M. tuberculosis
Primary human macrophages were generated from peripheral
blood obtained from healthy consented subjects (approved by
Regional NHS Research Ethics Committee) and were infected with
M. tuberculosis H37Rv (at MOI of 5:1) for 1 h, repeatedly washed and
then incubated for times indicated in the presence of compounds as
described. Cells were washed, lysed and plated onto Middlebrook
7H11 agar plates (after serial dilution). Colony-forming units were
enumerated after incubation at 37°C. Experiments were carried out in
triplicate. Results are representative of three separate experiments.
Zebrafish experiments
Zebrafish experiments were approved by the Local ethical review
panel of the Sheffield University Project applications and amend-
ments committee in accordance with UK legislation and were
carried out in accordance with Arrive guidelines. Zebrafish (Danio
rerio, AB strain), sourced in house, were used at 1–2 days post-
fertilization and were housed in Home Office-approved aquaria
facilities in the Bateson Centre and the Department of Infection and
Immunity, University of Sheffield.
Bacterial infection
Wild-type Zebrafish were injected with a red fluorescently tagged
M. marinum strain M (ATCC #BAA-535), containing the pSMT3-
Crimson vector (van der Sar et al, 2009). Approximately 125 colony-
forming units (CFU) of bacteria were injected into the yolk sac
circulation valley at 28 hpf as previously described (Benard et al,
2012). Larvae were imaged at 120 hpf on a Zeiss LSM510 NLO upright
microscope using a Zeiss Epiplan-Neofluar 2.5× objective (NA0.06).
The investigator was not blinded to the treatment condition due to
the need to separate the infectious agent from the laboratory environ-
ment where the fish were sited. Analysis of total fluorescence
throughout the larvae was performed using Volocity software.
In vivo autophagy assay
RNA for the fluorescent LC3 construct (pDestCMV:RFP.GFP.LC3)
was injected into Zebrafish embryos at the one-cell stage. At 1 dpf,
selected embryos were dechorionated manually and incubated for
24 h in vehicle-only control (DMSO 0.01%), rapamycin (1 lM) or
carbamazepine (50 lM) in the presence of chloroquine (2.5 lM) to
delay degradation of autophagosomes. A section of muscle ventral
to the dorsal fin was imaged in approximately 25 z-planes (2 lm),
and autophagosomes were counted in a single composite image of
all z-planes. The investigator was blinded to the treatment condi-
tion. A laboratory member not associated with this project used a
coding system unknown to the observer. The data are expressed as
the mean + SEM. n = at least 15, performed as 3 independent exper-
iments. See Supplementary Methods for details.
Mouse in vivo infection model
Specific-pathogen-free female C57BL/6 mice were challenged with
multidrug-resistant (MDR) M. tuberculosis clinical strains CSU87
(which is resistant to all first line anti-mycobacterial antibiotics) or
CSU39 (a less virulent isolate) or a clinical drug-sensitive strain
(SA310) using a Glass-Col (Terre Haute, Inc.) aerosol generator cali-
brated to deliver 50–100 bacteria into the lungs of each mouse as
previously described (Ordway et al, 2006, 2008). On Day 1 after
infection, enumeration of bacteria was performed on two mice.
Treatment was started from Day 20 to Day 49 after infection
and consisted of the following groups: Control (saline; 0.2 ml per
mouse by gavage once daily); RIF/INH (rifampicin 10 mg/kg, isonia-
zid 25 mg/kg; by gavage once daily); and CBZ (carbamazepine
50 mg/kg; i.p. once daily). On days 20, 35 and 50 following
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infection, bacterial loads in the lungs and spleen, lung and spleen
histology, and flow cytometry were determined in 5 mice from each
group. Bacterial counts were determined by plating serial dilutions
of homogenates of lungs on nutrient 7H11 agar and counting colony-
forming units after incubation at 37°C. Histology and flow cytometry
analysis was performed as previously described (Ordway et al, 2006,
2008; see Supplementary Methods). All experimental protocols were
approved by the Animal Care and Usage Committee of Colorado
State University, and experiments were performed in accordance
with NIH guidelines. To minimize bias, two groups of independent
researchers performed the experiment. One group dosed the animals,
whereas the second group determined bacterial burden in the differ-
ent organs. Lesion scores were determined in a blinded fashion.
Autophagy analysis in mammalian cell culture
Endogenous LC3-II levels, which directly correlate with autophago-
some numbers (Kabeya et al, 2000), were detected with anti-LC3
antibody and densitometric analysis, where performed, which is
expressed relative to actin. To assess autophagic flux, LC3-II was
measured in the presence of 400 nM bafilomycin A1 (treated in the
last 4 h), which clamps LC3-II/ autophagosome degradation (Klionsky
et al, 2008). This assay has been established and validated
previously with various autophagy modulators (Sarkar et al, 2007).
Clearance of mutant A53T a-synuclein was performed as previously
described (Sarkar et al, 2007; see Supplementary Methods).
Confocal immunofluorescence
Primary human macrophages were grown on glass coverslips,
treated as described, rinsed with PBS, fixed with methanol and
permeabilized with 0.1% Triton X-100 (Sigma) before incubation
with primary and then secondary antibodies as previous described
(Floto et al, 2005, 2006).
Myo-inositol effects on autophagosome formation
Raw 264.7 TL macrophages were seeded on glass-bottomed
culture dishes at 0.3 × 106 per well (Matek). They were then
incubated for 24 h in RPMI 1640, with no myo-inositol, normal
media (containing 200 lM of myo-inositol) or excess myo-inositol
(5 mM), with or without CBZ (50 lM). They were then imaged
under the LSM780, and autophagosome numbers were quantified
using Volocity software.
Dictyostelium infection model
Wild-type and mutant Dictyostelium discoideum AX2 strains were
grown axenically, resuspended in KK2 buffer and incubated with
M. abscessus (ATCC 1997) expressing Lux AB as previously
described (Renna et al, 2011) at an MOI of 0.01:1 for 2 h. Viable
mycobacteria were quantified by measuring luminescence as previ-
ously described (Renna et al, 2011). Experiments were performed in
sextuplicate on at least 3 separate occasions. See Supplementary
Methods for details.
Measurements of myo-inositol uptake, levels of inositol
1,4,5-trisphosphate and phosphatidylinositol bisphosphate
Myo-inositol uptake assay
RAW 264.7 cells were treated with carbamazepine (CBZ 200 lM),
or vehicle control (DMSO) for 3 ½ h in standard culture media
before then being resuspended in flux media (143 mM NaCl, 5 mM
KCl, 2 mM CaCl2, 1.2 mM MgCl2, 10 mM HEPES; pH 7.4) supple-
mented with 0.02 mM myo-inositol with or without CBZ for 30 min.
Cells were then resuspended in fresh flux media or sodium-free flux
media (143 mM N-methyl-d-glutamine (NMDG), 5 mM KCl, 2 mM
CaCl2, 1.2 mM MgCl2, 10 mM HEPES; pH 7.4) containing 1 lCi of
3H myo-inositol (PerkinElmer) and incubated at 37°C for times indi-
cated before being washed in ice-cold PBS and lysed in 0.25 M
NaOH overnight at 4°C. Cell-associated radiation was quantified by
scintillation.
Quantification of phosphatidylinositol bisphosphate (PIP2)
RAW 264.7 cells were treated with carbamazepine (200 lM), or
vehicle control (DMSO) for 24 h, the media replaced with ice-cold
1 M HCl. Following chloroform/methanol extraction and phosphate
methylation, PIP2 species were quantified by HPLC-MS as previ-
ously described (Clark et al, 2011).
Inositol 1,4,5-trisphosphate (IP3 1,4,5) measurements
RAW 264.7 cells were treated with carbamazepine (200 lM), lith-
ium chloride (10 mM) or vehicle control (DMSO) for 48 h, washed
with fresh media (and compounds) for 5 min, then scraped, spun
◀ Figure 4. Carbamazepine triggers mTOR-independent autophagy through myo-inositol depletion.A Effect on intracellular killing of luminescent mycobacteria in primary human macrophages of CBZ (50 lM), other dibenzazepines (opipramol, 100 ng/ml; lofepramine,
200 ng/ml; trimipramine, 50 ng/ml), mianserin (200 ng/ml) and the cardiac-specific SCN5A antagonist, flecainide (2 lg/ml). P-values, unpaired Student’s t-test
(n = ≥ 6) (compared to vehicle alone): CBZ 0.0001; opipramol 0.0005; lofepramine 0.0001; trimipramine 1 × 105.
B CBZ inhibits Na+-dependent myo-inositol uptake by macrophages. Rates of [3H]myo-inositol accumulation within cells were determined in the presence (squares) or
absence (circles) of extracellular Na+ during treatment with CBZ (50 lM; red) or vehicle alone (white). P-values, unpaired Student’s t-test (n = 6) (compared to vehicle
alone): CBZ 9.2 × 108.
C Sodium-dependent myo-inositol uptake (at 5 min) by macrophages is reduced by siRNA knock-down of the Na+–inositol co-transporter SLC5A3 (SMIT-1) under which
conditions co-treatment with CBZ (50 lM; red) caused no additional inhibition of inositol uptake.
D Effect on intracellular killing of luminescent mycobacteria in primary human macrophages of (i) siRNA knock-down of the Na+–inositol co-transporter SLC5A3
(SMIT-1) (P-values, unpaired Student’s t-test (n = 3) siSLC5A3 compared to siControl: 0.009; siControl + CBZ compared to vehicle alone: 0.0067) and (ii) incubation
with excess extracellular myo-inositol with (red) or without (white) treatment with CBZ at 50 lM (n = 3).
E Effect of depleting and adding excess myo-inositol on LC3-II mCherry autophagosome formation in RAW 264.7 macrophages. Myo-inositol depletion increases
autophagosome formation (white), with no significant additional change with CBZ treatment (red). Excess myo-inositol further reduces autophagosome number
(grey). P-values, unpaired Student’s t-test (n = 3) (compared to myo-inositol-free): 0.2 lM 0.013, 200 lM 0.01; 0.2 lM compared 0.2 lM + CBZ: 0.023. Scale bar
represents 40 lm.
Data information: *P < 0.05; **P < 0.005. All experiments were carried out at least in triplicate and on at least 3 separate occasions.
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and resuspended in ice-cold PBS. Following trichloroacetic
acid/1,1,2-trichloro-1,2,2-trifluoroethane/trioctylamine extraction,
IP3 were measured using the inositol (1,4,5) trisphosphate
3H radio-
receptor assay kit (PerkinElmer Life Sciences) following manufac-
turer’s instructions.
Mitochondrial Ca2+ measurements
HeLa cells stably expressing mt-cameleon were seeded onto uncoated
35-mm glass-bottomed dishes (MatTek Corporation), grown to
40–70% confluence then treated with 50 lM carbamazepine
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Figure 5. Carbamazepine induces autophagy through decreased IP3 signalling.
A Phospholipase C and IP3 receptor regulate autophagic killing of mycobacteria in Dictyostelium. Wild-type (WT, black) and mutant Dictyostelium AX2
strains were grown axenically and incubated with M. abscessus-lux (Renna et al, 2011) at an MOI of 0.01:1. M. abscessus-lux with no Dictyostelium (white)
were grown under identical conditions as a control. Viable mycobacteria were quantified by measuring luminescence at 2 h post-infection. Mutant strains
tested: mipp1 (multiple inositol polyphosphate phosphatase null), I6KA (inositol hexakisphosphate phosphate kinase null); plc (phospholipase C null);
IP3R (inositol (1,4,5)-trisphosphate receptor null mutant iplA-). P-values, unpaired Student’s t-test (n = 3) (compared to wild-type): PLC 0.01; IP3R
0.007.
B Quantification by mass spectroscopy of levels of C18:0 PIP2 species in macrophages following treatment with CBZ (red) or vehicle control
(white). SA- C18:0/C20:4. P-values, unpaired Student’s t-test (n = 3) (compared to vehicle alone): SA 6.6 × 109, 20:3 1.6 × 106, 18:2 3.5 × 108, 18:1
3.2 × 104.
C Levels of basal IP3 (1,4,5) in macrophages following treatment with CBZ (red), lithium (white) or vehicle alone (black) for 24 h (top) or 48 h (bottom). P-values,
unpaired Student’s t-test (n ≥ 3) (compared to vehicle alone): CBZ 24 h 0.00007; CBZ 24 h 0.0013; LiCl 24 h 0.00005; LiCl 48 h 0.04.
D Resting levels of mitochondrial calcium (monitored by mt-Cameleon sensor expression) are reduced by CBZ treatment (red) compared to controls.
(i) Representative calcium recordings of individual mitochondria from CBZ-treated (red) or control (black) cells, matched for similar fluorescence levels after
ionomycin addition (Fiono; arrow) showing lower resting mitochondrial calcium levels after treatment with CBZ. (ii) Normalized mitochondrial calcium levels
(F/Fiono) from cells treated with CBZ (red) or vehicle alone (white). P-values, unpaired Student’s t-test (n ≥ 20) (compared to vehicle alone): 9.5 × 10
15.
E, F CBZ treatment of macrophages results in (E) a decrease in cellular ATP and consequently (F) increased phosphorylation of AMP kinase (AMPK) and ULK1 (ULK).
P-values, unpaired Student’s t-test (n = 3) (compared to vehicle alone): 0.00003.
G Model for mechanism of autophagy induction by CBZ. Inhibition of the Na+ channel SCN5A leads to reduced activity of the Na+–inositol co-transported SLC5A3
leading to a drop in cellular inositol levels. The subsequent reduction in PIP2 (4,5) leads to a fall in basal IP3 (1,4,5) and reduced mitochondrial Ca
2+ levels. The
resultant fall in cellular ATP activates AMP kinase and subsequently ULK1 to trigger autophagic disposal of mycobacterial killing.
Data information: *P < 0.05; **P < 0.005. All experiments were carried out at least in triplicate and on at least three separate occasions.
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or vehicle alone for 24 h. Shortly, before imaging, cells were rinsed
twice and maintained in calcium containing Hanks’ balanced salt
solution (HBSS, Gibco) supplemented with 1 mM HEPES (Sigma)
and 20% glucose at 37 °C. Fluorescence imaging was achieved as
previously described (Tolhurst et al, 2011), based on Palmer et al
(2006). Excitation was achieved at 435  10 nm using a 75-W
xenon arc lamp and a monochromator (Cairn Research) controlled
by MetaFluor software (Molecular Devices). CFP and YFP
emissions were separated using a Cairn Optosplit II Image splitter
and acquired with an Orca-ER digital camera (Hamamatsu) at
470  24 and 535  30 nm, respectively. Cells were excited every
5 s, and fluorescence was recorded from individual mitochondria
(30–35 in each experiment), background-corrected and expressed
as the ratio of CFP over YFP. Once fluorescence signals had stabi-
lized and the temperature equilibrated, cells were imaged at rest
for at least 5 min (Rbasal) before 10 lM ionomycin/10 mM CaCl2
was added to the bath to achieve a reference fluorescence value
(Riono) by which separate experiments could be compared
(expressed as Rbasal/Riono). Experiments were carried out on at
least three separate occasions and with 3 or more individual wells
per condition.
ATP measurement
Primary human macrophages were cultured in white flat-bottom
medium-binding 96-well plates (Greiner Bio; seeding density:
3 × 104/well) and were treated with carbamazepine (50 lM for
24 h, supplemented with fresh media for the last 20 min) or vehicle
(DMSO). Cellular ATP concentrations (measured in triplicate inde-
pendent samples) were assayed using CellTiter Glow (Promega)
following the manufacturer’s instructions. Experiments were
performed on at least three separate occasions.
Statistics
Sample sizes for in vitro experiments were estimated based on
previous experience of similar assays and the effect size observed in
preliminary experiments. No samples were excluded from analysis.
All samples were genetically identical prior to allocation of treat-
ments.
For the assay of autophagy induction in zebrafish, sample size
was calculated from experimental data giving a standard deviation
of 1,040 autophagosomes and an expected meaningful difference
of 1,100 autophagosomes. For 80% confidence, this requires at
least 14 per group (n = 2 × 7.9 × SD2/D2). This was performed as
three independent experiments with 5 larvae in each group, giving
a total of 15 larvae per condition. Animals had to be healthy and
express the RNA construct to be included in analysis. These were
prespecified. For the assay of M. marinum infection burden in
zebrafish, sample size was calculated from preliminary data giving
a standard deviation of 7.75 arbitrary units and an expected mean-
ingful difference of 10 arbitrary units. For 90% confidence, this
requires at least 13 per group (n = 2 × 7.9 × SD2/D2). This was
performed as three independent experiments with 5 larvae in each
group, giving a total of 15 larvae per condition. No animals were
excluded from analysis. Formal randomization was not performed.
For the mice experiments, sample size estimates were made based
on other similar experiments performed on these (and other)
MDR-TB strains and other antimicrobial compounds. No animals
were excluded from analysis. For mice experiments, all animals
were genetically identical and treatment groups were assigned
prior to infection.
Unless where otherwise stated, P-values for all assays were deter-
mined using two-tailed Student’s t-test where the data were known
or tested (by Sigmaplot statistics package) to be normally distrib-
uted. Where appropriate, individual data points were also plotted
out to confirm a normal distribution. A P-value of 0.05 or less was
considered significant. Experiments were performed on at least
three separate occasions with at least triplicate samples for each
condition and represented as mean  standard deviation (sd) or
standard error (se). All experiments conformed to the principles set
out in the WMA Declaration of Helsinki and the Department of
Health and Human Services Belmont Report.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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The paper explained
Problem
The increase in infections with multidrug-resistant (MDR) and exten-
sive drug-resistant (XDR) MTB, requiring longer and more toxic drug
regimens which often fail, has created significant barriers to effective
treatment of tuberculosis in both well-resourced and resource-poor
settings (Nathanson et al, 2010; Lienhardt et al, 2012) and illustrates
the pressing need for new, more effective therapies.
Results
Here, we show that screening of FDA-approved drugs identified
compounds able to stimulate autophagic killing of mycobacteria at
therapeutic concentrations. One such compound, carbamazepine,
triggers autophagy independently of mTOR (revealing a novel myo-
inositol-dependent activation pathway) and effectively targets multi-
drug-resistant M. tuberculosis in vivo stimulating both innate and
adaptive immunity. We also demonstrate that in vivo autophagic kill-
ing of M. tuberculosis by carbamazepine is strain-specific, suggesting
that autophagy resistance factors may have developed in certain clini-
cal isolates.
Impact
Pharmacological stimulation of autophagy by carbamazepine avoids
the immunosuppressive effects of mTOR inhibition seen with rapamy-
cin, promoting both innate and adaptive immune responses to myco-
bacterial infection, and represents proof of concept for a novel
therapeutic strategy unaffected by bacterial resistance to conventional
antibiotics. Our work suggests that while M. tuberculosis can success-
fully overcome physiological processes mediating intracellular killing
and survive within macrophages, it remains vulnerable to mTOR-
independent autophagic clearance.
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